Fig. 3: Primary endpoint and associated analyses.

All panels show the same x-axis of days since initial programming and use equivalent colors for Remote Internet-Based Adjustment (RIBA) (blue line) and In-Clinic (IC) (green dashed line) groups. a Mean time to at least one point improvement on the Patient Global Impression of Change (PGI-C), the minimal clinically important difference (MCID) on this scale, over the 90-day study period in the intention-to-treat (ITT) cohort. Colored area around the lines represents 95% confidence interval. b Probability of not achieving at least one-point PGI-C improvement over the 90-day study period in both study arms. Area under the Kaplan-Meier survival curve represents the mean time to at least one-point improvement on the PGI-C up to 90 days. Panels a and b contain data from n = 48 independent individuals in both study groups (ITT cohort) c) mean number of cumulative titration visits per patient over the 90-day study period in the RIBA and IC groups. d, e Percentage of patients whose symptoms improved by at least one-point on the Global Impression of Change Scale as rated by the patient (PGI-C) and clinician (CGI-C) over the 90-day study period in both study arms, respectively. Panels c, d, and e contain data from n = 38 independent individuals in the RIBA group and n = 43 independent individuals in the IC group (Per-Protocol cohort).